Baili Tianheng announced that t-Bren independently developed by the company was used in phase III clinical trials of unresectable locally advanced or metastatic HER2 positive breast cancer where treatment with trastuzumab and paclitaxel failed. According to the independent data monitoring committee, the analysis reached the main end point of progression-free survival. This is the first phase III clinical study where this ADC reached its primary endpoint.

Baili Tianheng announced that t-Bren independently developed by the company was used in phase III clinical trials of unresectable locally advanced or metastatic HER2 positive breast cancer where treatment with trastuzumab and paclitaxel failed. According to the independent data monitoring committee, the analysis reached the main end point of progression-free survival. This is the first phase III clinical study where this ADC reached its primary endpoint.